CLNN

SEC source: 0001835544-26-000011 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By SymBiosis II, LLC

Disclosed balance after: 537,410

SEC source: 0001835544-26-000011 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By SymBiosis II, LLC

Disclosed balance after: 544,508

SEC source: 0001437749-26-004897 · rdgdoc.xml · derivative · entry 1

Kiernan Matthew · CIK 0001993183 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,755

Underlying: common stock · 2,755 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 2,755 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

SEC source: 0001437749-26-004913 · rdgdoc.xml · derivative · entry 1

McLaughlin Vallerie · CIK 0001876030 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,030

Underlying: common stock · 3,030 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 3,030 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

SEC source: 0001437749-26-004899 · rdgdoc.xml · derivative · entry 1

Gay Jonathon · CIK 0001835422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,271

Underlying: common stock · 3,271 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 3,271 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

SEC source: 0001437749-26-004911 · rdgdoc.xml · derivative · entry 1

WILCOX REED N · CIK 0001266609 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,306

Underlying: common stock · 3,306 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 3,306 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

SEC source: 0001437749-26-004906 · rdgdoc.xml · derivative · entry 1

MATLIN DAVID J · CIK 0001251956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,372

Underlying: common stock · 5,372 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 5,372 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

SEC source: 0001437749-26-004909 · rdgdoc.xml · derivative · entry 1

Mosca Alison · CIK 0001835537 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,201

Underlying: common stock · 4,201 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 4,201 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

SEC source: 0001437749-26-004903 · rdgdoc.xml · derivative · entry 1

Desai Arjun JJ · CIK 0001982985 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,168

Underlying: common stock · 3,168 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 3,168 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

SEC source: 0001437749-26-004901 · rdgdoc.xml · derivative · entry 1

Jacobovitz Shalom · CIK 0001835556 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,098

Underlying: common stock · 4,098 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 4,098 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.

SEC source: 0001835544-26-000010 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 550,000

SEC source: 0001835544-26-000009 · primary_doc.xml · nonDerivative · entry 3

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By SymBiosis II, LLC

Disclosed balance after: 555,559

SEC source: 0001835544-26-000009 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 559,359

SEC source: 0001835544-26-000009 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 565,045

SEC source: 0001835544-26-000008 · primary_doc.xml · nonDerivative · entry 3

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By SymBiosis II, LLC

Disclosed balance after: 580,329

SEC source: 0001835544-26-000008 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 589,046

SEC source: 0001835544-26-000008 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 593,185

SEC source: 0001835544-26-000007 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 599,603

SEC source: 0001437749-26-001912 · rdgdoc.xml · derivative · entry 1

Mortenson Mark · CIK 0001835427 · Chief Science Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: common stock · 75,000 shares

Expires 2036-01-21

F1 · derivative.exercise_date: This option was granted on January 22, 2026 as an option for 75,000 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The options vest immediately upon grant.

SEC source: 0001437749-26-001915 · rdgdoc.xml · derivative · entry 1

BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: common stock · 35,000 shares

Expires 2036-01-21

F1 · derivative.exercise_date: This option was granted on January 22, 2026 as an option for 35,000 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The options vest immediately upon grant.

SEC source: 0001835544-26-000007 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 605,159

SEC source: 0001437749-26-001910 · rdgdoc.xml · derivative · entry 1

Etherington Robert Dee · CIK 0001835330 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: common stock · 75,000 shares

Expires 2036-01-21

F1 · derivative.exercise_date: This option was granted on January 22, 2026 as an option for 75,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The options vest immediately upon grant.

SEC source: 0001835544-26-000006 · primary_doc.xml · nonDerivative · entry 3

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 617,824

SEC source: 0001835544-26-000006 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 629,943

SEC source: 0001835544-26-000006 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 642,375

SEC source: 0001835544-26-000005 · primary_doc.xml · nonDerivative · entry 3

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 650,298

SEC source: 0001835544-26-000005 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 662,861

SEC source: 0001437749-26-001170 · rdgdoc.xml · derivative · entry 3

MATLIN DAVID J · CIK 0001251956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,333

Underlying: common stock · Not disclosed shares

Expires 2031-01-13

F5 · derivative.exercise_price: The exercise price for each Series B Warrant will increase from $6.00 to $12.50 per share if: (i) the Series B Warrant is exercised prior to the Company's public announcement of its receipt of written approval from the FDA of its NDA for CNM-Au8 in ALS or (ii) the VWAP of the Company's common stock is equal to or greater than $25.00 on the associated measurement date. The exercise price of the Series B Warrant will increase to $10.00 per share if the VWAP of the Company's common stock is equal to or greater than $20.00 on the associated measurement date.

F6 · shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.

F2 · price: The price of each Unit is $6.50 consisting of one share of Common Stock of Clene, one Series A Warrant and one Series B Warrant.

F6 · derivative.underlying_shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.

SEC source: 0001437749-26-001170 · rdgdoc.xml · derivative · entry 2

MATLIN DAVID J · CIK 0001251956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: common stock · Not disclosed shares

Expires 2029-01-13

F3 · derivative.exercise_price: The exercise price of each Series A Warrant will increase from $6.00 to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the U.S. Food and Drug Administration's (the "FDA") posted action date under the Prescription Drug User Fee Act for the Company's new drug application ("NDA") for CNM-Au8 (the "Series A Trigger Announcement "); or (b) the volume-weighted average price (the "VWAP") of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the Series A Trigger Announcement.

F4 · shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.

F2 · price: The price of each Unit is $6.50 consisting of one share of Common Stock of Clene, one Series A Warrant and one Series B Warrant.

F4 · derivative.underlying_shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.

SEC source: 0001437749-26-001170 · rdgdoc.xml · nonDerivative · entry 1

MATLIN DAVID J · CIK 0001251956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 477,824

F1 · date: The reporting person entered into a Securities Purchase Agreement with Clene Inc. and the other parties thereto, dated January 8, 2026, for the purchase of 33,333 shares of the Company's common stock, Series A Warrants to purchase 40,000 shares of the Company's common stock and Series B Warrants to purchase 93,333 shares of the Company's common stock, closing effective January 13, 2026.

F2 · price: The price of each Unit is $6.50 consisting of one share of Common Stock of Clene, one Series A Warrant and one Series B Warrant.

SEC source: 0001104659-26-003464 · tm263117-1_4seq1.xml · derivative · entry 9

Mosca Alison · CIK 0001835537 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By LLC

Disclosed balance after: 46,667

Underlying: Common Stock · Not disclosed shares

Expires 2029-01-09

F11 · derivative.exercise_price: The exercise price for each Series B Warrant will increase from $6.00 to $12.50 per share if: (i) the Series B Warrant is exercised prior to the Company's public announcement of its receipt of written approval from the FDA of its NDA for CNM-Au8 in ALS or (ii) the VWAP of the Company's common stock is equal to or greater than $25.00 on the associated measurement date. The exercise price of the Series B Warrant will increase to $10.00 per share if the VWAP of the Company's common stock is equal to or greater than $20.00 on the associated measurement date.

F12 · shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.

F4 · price: The price of each Unit is $6.50; one Unit consists of one share of Common Stock of Clene Inc., one Series A Warrant and one Series B Warrant.

F12 · derivative.underlying_shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.

F2 · ownership.nature: The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

SEC source: 0001104659-26-003464 · tm263117-1_4seq1.xml · derivative · entry 8

Mosca Alison · CIK 0001835537 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By LLC

Disclosed balance after: 20,000

Underlying: Common Stock · Not disclosed shares

Expires 2029-01-09

F9 · derivative.exercise_price: The exercise price for each Series A Warrant will increase from $6.00 to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the U.S. Food and Drug Administration's (the "FDA") posted action date under the Prescription Drugs User Fee Act for the Company's new drug application ("NDA") for CNM-Au8 (the "Series A Trigger Announcement") or (b) the volume-weighted average price (the "VWAP") of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the Series A Trigger Announcement.

F10 · shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.

F4 · price: The price of each Unit is $6.50; one Unit consists of one share of Common Stock of Clene Inc., one Series A Warrant and one Series B Warrant.

F10 · derivative.underlying_shares: The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.

F2 · ownership.nature: The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

SEC source: 0001104659-26-003464 · tm263117-1_4seq1.xml · nonDerivative · entry 2

Mosca Alison · CIK 0001835537 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By LLC

Disclosed balance after: 280,500

F3 · date: Kensington Clene 2021, LLC entered into a Securities Purchase Agreement with Clene Inc. and the other parties thereto, dated January 8, 2026, for the purchase of 16,667 shares of the Company's common stock, Series A Warrants to purchase 20,000 shares of the Company's common Stock and Series B Warrants to purchase 46,667 shares of the Company's common stock, closing effective January 13, 2026.

F4 · price: The price of each Unit is $6.50; one Unit consists of one share of Common Stock of Clene Inc., one Series A Warrant and one Series B Warrant.

F2 · ownership.nature: The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

SEC source: 0001835544-26-000005 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 682,482

SEC source: 0001835544-26-000003 · primary_doc.xml · nonDerivative · entry 3

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 708,587

SEC source: 0001835544-26-000003 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 741,292

SEC source: 0001104659-26-003464 · tm263117-1_4seq1.xml · derivative · entry 7

Mosca Alison · CIK 0001835537 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By LLC

Disclosed balance after: 62,500

Underlying: Common Stock · 57,219 shares

Expires not disclosed

F1 · kind: The transaction reported on this line represents a distribution in kind by the limited liability company to a limited partner for no consideration.

F8 · derivative.expiration_date: The Tranche A Warrants will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the FDA accepts a New Drug Application from the Company. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

F2 · ownership.nature: The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

SEC source: 0001104659-26-003464 · tm263117-1_4seq1.xml · derivative · entry 6

Mosca Alison · CIK 0001835537 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By LLC

Disclosed balance after: 62,500

Underlying: Common Stock · 57,219 shares

Expires not disclosed

F1 · kind: The transaction reported on this line represents a distribution in kind by the limited liability company to a limited partner for no consideration.

F7 · derivative.expiration_date: The Tranche B Warrants will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the FDA approval of a New Drug Application from the Company. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

F2 · ownership.nature: The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

SEC source: 0001104659-26-003464 · tm263117-1_4seq1.xml · nonDerivative · entry 1

Mosca Alison · CIK 0001835537 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By LLC

Disclosed balance after: 263,833

F1 · kind: The transaction reported on this line represents a distribution in kind by the limited liability company to a limited partner for no consideration.

F2 · ownership.nature: The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

SEC source: 0001835544-26-000003 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 750,367

SEC source: 0001835544-26-000002 · primary_doc.xml · nonDerivative · entry 3

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 753,562

SEC source: 0001835544-26-000002 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 757,500

SEC source: 0001835544-26-000002 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 760,611

SEC source: 0001835544-26-000001 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 766,480

SEC source: 0001835544-26-000001 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 770,495

SEC source: 0001835544-25-000006 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 783,590

SEC source: 0001835544-25-000006 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 787,728

SEC source: 0001835544-25-000005 · primary_doc.xml · nonDerivative · entry 4

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 795,824

SEC source: 0001835544-25-000005 · primary_doc.xml · nonDerivative · entry 3

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 799,174

SEC source: 0001835544-25-000005 · primary_doc.xml · derivative · entry 5

Ugwumba Chidozie · CIK 0001835544 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Symbiosis II, LLC

Disclosed balance after: 0

Underlying: Common Stock · 424,358 shares

Expires not disclosed

F2 · derivative.expiration_date: The pre-funded warrants are indefinite with no specified termination date.